
Incorporating artificial intelligence (AI)-based technology, Neosoma HGG reportedly demonstrated a 95.5 percent accuracy rate in measuring brain tumor volume on brain magnetic resonance imaging (MRI) scans at various points during the treatment of patients with high-grade gliomas.





























